Immunotherapy with NK cells

UMIN ID: UMIN000002134

Registered date:08/07/2009

Basic Information

• Health condition(s) or Problem(s) studied: Clinical study to investigate safety and efficacy on NK cells to health and cancer
• Date of first enrollment: 2009/04/01
• Target sample size: 15
• Countries of recruitment: Japan,Asia(except Japan)
• Study type: Interventional
• Intervention(s): To investigate safety and efficacy on NK cells for human

Outcome(s)

• Primary Outcome: Safety
• Secondary Outcome: Antitumor effect Progression-free survival Overall survival QOL Immunological responses

Key inclusion & exclusion criteria

• Age minimum: 5years-old
• Age maximum: 120years-old
• Gender: Male and Female
• Exclude criteria: 1.Uncontrollable infection 2.Serious cardiac disease 3.Active autoimmune disease 4.Pulmonary fibrosis or interstitial pneumonia, or their history, or predisposition to them 5.Serious drug allergy

Related Information

• Primary Sponsor: Kuramae clinic
• Source(s) of Monetary Support: Kuramae clinic